T1	DISO 16 27	hemorragias
#1	AnnotatorNotes T1	C0019080; Hemorrhage; Pathologic Function
T2	CHEM 59 70	enoxaparina
#2	AnnotatorNotes T2	C0206460; enoxaparin; Organic Chemical · Pharmacologic Substance
T3	DISO 74 90	angina inestable
#3	AnnotatorNotes T3	C0002965; Angina, Unstable; Disease or Syndrome
T4	CHEM 125 136	ENoxaparina
#4	AnnotatorNotes T4	C0206460; enoxaparin; Organic Chemical · Pharmacologic Substance
T5	CHEM 140 163	Heparina No Fraccionada
#5	AnnotatorNotes T5	C0019134; heparin; Organic Chemical · Biologically Active Substance · Pharmacologic Substance
T6	DISO 167 183	Angina Inestable
#6	AnnotatorNotes T6	C0002965; Angina, Unstable; Disease or Syndrome
T7	PROC 214 260	estudio prospectivo, aleatorizado y controlado
#7	AnnotatorNotes T7	C0033522; Prospective Studies; Research Activity + C0206035; Controlled Clinical Trials, Randomized; Research Activity
T8	DISO 276 290	complicaciones
#8	AnnotatorNotes T8	C0009566; Complication; Pathologic Function
T9	PROC 306 317	tratamiento
#9	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	CHEM 336 347	enoxaparina
#10	AnnotatorNotes T10	C0206460; enoxaparin; Organic Chemical · Pharmacologic Substance
T11	CHEM 413 416	HNF
#11	AnnotatorNotes T11	C0019134; heparin; Organic Chemical · Biologically Active Substance · Pharmacologic Substance
T12	PROC 479 483	TTPa
#12	AnnotatorNotes T12	C0030605; Activated Partial Thromboplastin Time measurement; Laboratory Procedure
T13	ANAT 524 531	séricos
#13	AnnotatorNotes T13	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T14	CHEM 535 542	anti-Xa
#14	AnnotatorNotes T14	C0019139; Heparin, Low-Molecular-Weight; Organic Chemical · Pharmacologic Substance (?)
T15	PROC 581 592	tratamiento
#15	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	PROC 516 542	niveles séricos de anti-Xa
T17	PROC 637 648	seguimiento
#16	AnnotatorNotes T17	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T18	PROC 739 752	angiográficas
#17	AnnotatorNotes T18	C0002978; angiogram; Diagnostic Procedure
T19	PROC 1017 1030	angiográficas
#18	AnnotatorNotes T19	C0002978; angiogram; Diagnostic Procedure
T20	CHEM 1062 1069	anti-Xa
#19	AnnotatorNotes T20	C0019139; Heparin, Low-Molecular-Weight; Organic Chemical · Pharmacologic Substance (?)
T21	CHEM 1096 1107	enoxaparina
#20	AnnotatorNotes T21	C0206460; enoxaparin; Organic Chemical · Pharmacologic Substance
T22	DISO 1167 1178	hemorragias
#21	AnnotatorNotes T22	C0019080; Hemorrhage; Pathologic Function
T23	PROC 1044 1069	niveles útiles de anti-Xa
T24	ANAT 1341 1357	cardiovasculares
#22	AnnotatorNotes T24	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T25	DISO 1333 1357	eventos cardiovasculares
#23	AnnotatorNotes T25	C1320716; Cardiovascular event; Finding
T26	CHEM 1502 1513	enoxaparina
#24	AnnotatorNotes T26	C0206460; enoxaparin; Organic Chemical · Pharmacologic Substance
T27	PROC 1571 1582	tratamiento
#25	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	DISO 1631 1642	hemorragias
#26	AnnotatorNotes T28	C0019080; Hemorrhage; Pathologic Function
T29	CHEM 1676 1687	enoxaparina
#27	AnnotatorNotes T29	C0206460; enoxaparin; Organic Chemical · Pharmacologic Substance
T30	PROC 1719 1730	seguimiento
#28	AnnotatorNotes T30	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T32	Dose 348 357	0.8 mg/kg
T33	Route 358 368	subcutánea
#29	AnnotatorNotes T33	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T34	Frequency 369 382	cada 12 horas
T35	Duration 391 397	5 días
T36	Route 417 428	intravenosa
#30	AnnotatorNotes T36	C1522726; Intravenous Route of Drug Administration; Functional Concept
T37	Duration 446 452	5 días
T38	Duration 545 564	las 4, 12, 24 horas
T39	Duration 651 658	30 días
T40	LIVB 832 841	pacientes
#31	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 895 904	pacientes
#32	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T43	LIVB 1083 1092	pacientes
#33	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T45	Spec_cue 1157 1166	riesgo de
T47	Duration 1547 1567	las primeras 4 horas
T48	Dose 40 55	dosis reducidas
#34	AnnotatorNotes T48	C0445550; Low dose; Quantitative Concept
T31	Duration 567 577	quinto día
T46	Dose 1658 1672	dosis reducida
#35	AnnotatorNotes T46	C0445550; Low dose; Quantitative Concept
T44	LIVB 855 869	sexo masculino
#36	AnnotatorNotes T44	C0025266; Male population group; Population Group
A1	Assertion T22 Speculated
R1	Speculation Arg1:T45 Arg2:T22	
T49	Neg_cue 939 941	No
T50	CONC 953 964	diferencias
A2	Assertion T50 Negated
#37	AnnotatorNotes T50	C1705241; Delta (difference); Quantitative Concept
R2	Negation Arg1:T49 Arg2:T50	
T51	Observation 94 105	alto riesgo
R3	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T51	
R4	Has_Dose_or_Strength Arg1:T2 Arg2:T48	
T52	Quantifier_or_Qualifier 28 35	totales
R5	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T52	
R6	Has_Dose_or_Strength Arg1:T10 Arg2:T32	
R7	Has_Route_or_Mode Arg1:T10 Arg2:T33	
R8	Has_Frequency Arg1:T10 Arg2:T34	
R9	Has_Duration_or_Interval Arg1:T10 Arg2:T35	
R10	Has_Route_or_Mode Arg1:T11 Arg2:T36	
R11	Has_Duration_or_Interval Arg1:T11 Arg2:T37	
R12	Causes Arg1:T9 Arg2:T8	
T53	Quantifier_or_Qualifier 429 437	continúa
R13	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T53	
R14	Overlap Arg1:T16 Arg2:T38	
R15	Overlap Arg1:T16 Arg2:T31	
R16	Has_Duration_or_Interval Arg1:T15 Arg2:T38	
R17	Has_Duration_or_Interval Arg1:T15 Arg2:T31	
R18	Overlap Arg1:T17 Arg2:T39	
T54	CONC 671 705	análisis univariado y multivariado
#38	AnnotatorNotes T54	C0026777; Multivariate Analysis; Quantitative Concept + C0683962; univariate statistics; Research Activity
T55	CONC 713 737	características clínicas
T56	CONC 713 728;739 752	características angiográficas
T57	CONC 990 1014	características clínicas
T58	CONC 1017 1030;990 1005	angiográficas características
R19	Experiences Arg1:T43 Arg2:T23	
R20	Experiences Arg1:T43 Arg2:T21	
T59	Quantifier_or_Qualifier 1179 1186	totales
R21	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T59	
R22	Location_of Arg1:T24 Arg2:T25	
T60	Quantifier_or_Qualifier 1358 1365	mayores
R23	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T60	
T61	Observation 1520 1540	niveles terapéuticos
R25	Causes Arg1:T26 Arg2:T61	
R26	After Arg1:T61 Arg2:T47	
R27	Has_Duration_or_Interval Arg1:T27 Arg2:T47	
T62	Quantifier_or_Qualifier 1643 1650	totales
R28	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T62	
R29	Has_Dose_or_Strength Arg1:T29 Arg2:T46	
T63	Neg_cue 149 151	No
T64	Quantifier_or_Qualifier 152 163	Fraccionada
A3	Assertion T64 Negated
R31	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T64	
R32	Negation Arg1:T63 Arg2:T64	
T65	LIVB 296 317	grupos de tratamiento
#39	AnnotatorNotes T65	C5205742; Treatment Group; Population Group
R33	Experiences Arg1:T65 Arg2:T9	
R34	Experiences Arg1:T65 Arg2:T8	
#40	AnnotatorNotes T51	C4319571; High risk; Finding
#41	AnnotatorNotes T52	C0439810; Total; Qualitative Concept
#42	AnnotatorNotes T53	C0549178; Continuous; Idea or Concept
#43	AnnotatorNotes T16	C0427612; Anti factor Xa measurement; Laboratory Procedure (?)
#44	AnnotatorNotes T23	C0427612; Anti factor Xa measurement; Laboratory Procedure (?)
#45	AnnotatorNotes T59	C0439810; Total; Qualitative Concept
A4	Assertion T59 Speculated
R35	Speculation Arg1:T45 Arg2:T59	
#46	AnnotatorNotes T60	C0205164; Major; Qualitative Concept
#47	AnnotatorNotes T62	C0439810; Total; Qualitative Concept
A5	Experiencer T43 Patient
A6	Experiencer T65 Patient
A7	Experiencer T40 Patient
A8	Experiencer T44 Patient
A9	Experiencer T41 Patient
